ストックスクリーナーアプリを入手
58.15
1.63%
0.93
アフターアワーズ：
58.15
前日終値:
$57.22
開ける：
$57.65
24時間の取引高:
1.86M
Relative Volume:
0.74
時価総額：
$14.41B
収益：
$2.38B
当期純損益:
$833.42M
株価収益率:
19.27
EPS:
3.0172
ネットキャッシュフロー:
$917.69M
1週間 パフォーマンス:
+2.20%
1か月 パフォーマンス:
+7.53%
6か月 パフォーマンス:
+40.90%
1年 パフォーマンス:
+46.92%
1日の値動き範囲:
$57.33
$59.09
1週間の範囲:
$56.33
$59.15
52週間の値動き範囲:
$33.76
$59.72
Exelixis Inc Stock (EXEL) Company Profile
Compare EXEL vs VRTX, REGN, MRNA, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
58.15 | 13.91B | 2.38B | 833.42M | 917.69M | 3.0172 |
VRTX
Vertex Pharmaceuticals Inc
|
514.99 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.90 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
182.56 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
963.79 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
368.08 | 39.20B | 5.76B | 514.49M | 1.10B | 4.4813 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-08 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2026-01-05 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2025-11-18 | 開始されました | Wolfe Research | Peer Perform |
| 2025-11-03 | ダウングレード | Guggenheim | Buy → Neutral |
| 2025-10-21 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-09-19 | 再開されました | Barclays | Equal Weight |
| 2025-09-17 | 再開されました | Barclays | Equal Weight |
| 2025-09-17 | 開始されました | Goldman | Buy |
| 2025-07-08 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-06-24 | アップグレード | Stephens | Equal-Weight → Overweight |
| 2025-02-24 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-01-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-01-24 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-12-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-17 | ダウングレード | BofA Securities | Buy → Neutral |
| 2024-10-16 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2024-09-19 | 開始されました | UBS | Neutral |
| 2024-04-11 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2023-12-19 | 開始されました | BTIG Research | Buy |
| 2023-12-15 | 開始されました | Citigroup | Buy |
| 2023-09-26 | 開始されました | H.C. Wainwright | Buy |
| 2023-08-22 | 繰り返されました | Oppenheimer | Outperform |
| 2023-08-08 | 開始されました | SVB Securities | Market Perform |
| 2023-07-11 | 再開されました | Morgan Stanley | Equal-Weight |
| 2023-05-10 | 再開されました | Piper Sandler | Overweight |
| 2023-03-09 | 開始されました | Wells Fargo | Overweight |
| 2023-01-26 | 開始されました | Credit Suisse | Outperform |
| 2022-10-18 | 開始されました | JMP Securities | Mkt Outperform |
| 2022-06-24 | 開始されました | BMO Capital Markets | Outperform |
| 2021-11-19 | 開始されました | Piper Sandler | Overweight |
| 2021-11-03 | 再開されました | Jefferies | Buy |
| 2021-10-07 | 開始されました | Jefferies | Buy |
| 2021-08-06 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-06-15 | 開始されました | H.C. Wainwright | Buy |
| 2021-05-18 | 再開されました | Goldman | Sell |
| 2021-03-31 | 開始されました | Credit Suisse | Outperform |
| 2021-03-12 | 開始されました | Wolfe Research | Outperform |
| 2020-03-04 | 開始されました | Barclays | Overweight |
| 2020-01-13 | 開始されました | SunTrust | Buy |
| 2019-11-13 | 開始されました | BofA/Merrill | Buy |
| 2019-03-18 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | 開始されました | Goldman | Neutral |
| 2018-09-10 | 開始されました | Morgan Stanley | Underweight |
| 2018-05-11 | 繰り返されました | Needham | Buy |
| 2017-10-17 | 繰り返されました | Needham | Buy |
| 2017-10-17 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2017-10-16 | 繰り返されました | SunTrust | Buy |
| 2017-09-22 | ダウングレード | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | 開始されました | RBC Capital Mkts | Outperform |
| 2017-09-12 | 繰り返されました | Needham | Buy |
| 2017-07-14 | 開始されました | SunTrust | Buy |
| 2017-03-31 | 開始されました | Needham | Buy |
| 2017-03-16 | 開始されました | Oppenheimer | Perform |
| 2017-02-28 | ダウングレード | Stifel | Buy → Hold |
| 2016-11-03 | 開始されました | Deutsche Bank | Buy |
| 2016-10-10 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | 繰り返されました | Stifel | Buy |
すべてを表示
Exelixis Inc (EXEL) 最新ニュース
Exelixis FDA Delay Moves Zanzalintinib Decision to March 2027 - TechStock²
Exelixis (EXEL) Stock Looks Undervalued On Earnings But Mixed On Value - webull.com
Form 8K Exelixis Inc For: 11 September By Investing.com - Investing.com Australia
EXEL Stock Slides After FDA Adds Three Months To Cancer Drug Review — William Blair Sees More Swings In Near Term - Stocktwits
IBD 50 Biotech Dives On Surprise Delay For Next-Gen Cancer Drug - Investor's Business Daily
FDA extends review of Exelixis drug application for metastatic colorectal cancer - Investing.com Nigeria
Exelixis Stock Slips as FDA Delays Cancer Drug Review, Analyst Weighs In - Benzinga
EXEL Looks 21.5% Overvalued on GF Value™ as PDUFA Delay Sparks Volatility - GuruFocus
FDA extends review of Exelixis’ colorectal cancer drug candidate - endpoints.news
US FDA extends review of Exelixis’ cancer drug - WSAU
Exelixis, Inc. (EXEL) Stock Price, News, Quote & History - ca.finance.yahoo.com
FDA extends Exelixis' zanzalintinib review by three months, pushing decision to March 2027 - AllSci
Exelixis Shares Fall 3.5% as FDA Extends Zanzalintinib Review by Three Months - Yahoo Finance
US FDA extends review of Exelixis' cancer drug - Reuters
Why is Exelixis stock sliding today? By Investing.com - Investing.com Canada
Exelixis stock falls as FDA extends zanzalintinib review By Investing.com - Investing.com South Africa
Exelixis stock falls as FDA extends zanzalintinib review - investing.com
EXEL Looks 24.3% Overvalued on GF Value™ - GuruFocus
Form 8K Exelixis Inc For: 11 September - Investing.com India
FDA Extends Review Timeline for Exelixis Cancer Drug - TipRanks
U.S. FDA extends review of Exelixis' cancer drug - Yahoo Finance
Handa Oncology Receives FDA Final Approval for OMCAZIO(TM) (cabozantinib) Capsules - Yahoo Finance
La FDA américaine prolonge l'examen du médicament anticancéreux d'Exelixis - TradingView
Die US-amerikanische FDA verlängert die Prüfung des Krebsmedikaments von Exelixis - TradingView
Discipline and Rules-Based Execution in EXEL Response - Stock Traders Daily
Adagene earns milestone under Exelixis ADC collaboration - BioWorld News
Adagene Inc. Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody® Antibody-Drug Conjugate Candidates - marketscreener.com
Adagene Receives Milestone Payment From Exelixis - marketscreener.com
Exelixis at Citigroup summit: building a second growth engine - Investing.com
Exelixis at Citigroup summit: building a second growth engine By Investing.com - Investing.com Canada
Exelixis, Inc. (EXEL) Latest Stock News & Headlines - Yahoo! Finance Canada
Cancer drug milestone brings new cash to Adagene (NASDAQ: ADAG) - Stock Titan
Adagene Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody® Antibody-Drug Conjugate Candidates - Yahoo! Finance Canada
Transcript : Exelixis, Inc. Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-08-2026 11 - marketscreener.com
Exelixis, Inc. v. MSN Laboratories Private Ltd. (Fed. Cir. 2026) - JD Supra
Exelixis at Wells Fargo conference: zanzalintinib takes center stage By Investing.com - Investing.com Canada
Exelixis, Inc. (EXEL) Stock Analysis: A Promising Biotech with Robust Revenue Growth and Strategic Partnerships - DirectorsTalk Interviews
Exelixis Stock Price Forecast. Should You Buy EXEL? - StockInvest.us
Exelixis (EXEL) Up 13.3% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Exelixis stock hits all-time high at 57.68 USD By Investing.com - Investing.com Australia
EXEL - Finviz
Exelixis stock hits all-time high at 57.68 USD - investing.com
Exelixis (EXEL) Receives a Hold from BMO Capital - The Globe and Mail
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September 2026 - BioSpace
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September - Business Wire
Exelixis secures Cabometyx exclusivity with patent win - BioWorld News
Exelixis: 'Hold' On Zanzalintinib Subpopulation Miss And STELLAR-304 H2 2026 Data - Seeking Alpha
Fed. Circ. Upholds Block On MSN Cancer Drug In Exelixis Win - Law360
Exelixis wins appeals court ruling upholding key patents, FDA approval barred until at least Jan 15, 2030 - TradingView
Exelixis Wins Appeal in Patent Case Against MSN Laboratories - marketscreener.com
EXEL Looks 18.3% Overvalued on GF Value™ After Patent Win - GuruFocus
Exelixis Inc (EXEL) 財務データ
収益
当期純利益
現金流量
EPS
0.14%
0.15%
大文字化:
|
ボリューム (24 時間):